Showing 5291-5300 of 5659 results for "".
- FDA Grants Breakthrough Therapy Designation for Actemra in Systemic Sclerosishttps://practicaldermatology.com/news/fda-grants-breakthrough-therapy-designation-for-actemra-in-systemic-sclerosis/2458929/Genentech, a member of the Roche Group, was granted FDA Breakthrough Therapy Designation status for Actemra® (tocilizumab) for systemic sclerosis, also known as scleroderma. This designation is intended to expedite the development and review of medicines with early signals of poten
- Radiesse from Merz Aesthetics Approved for Handshttps://practicaldermatology.com/news/radiesse-from-merz-aesthetics-approved-for-hands/2458934/Radiesse® from Merz Aesthetics received FDA approval for hand augmentation to correct volume loss in the dorsum of the hands. Radiesse® provides an immediate volumizing effect and can help to reduce the prom
- Encore Dermatology, Inc.: A New Specialty Dermatology Company Launcheshttps://practicaldermatology.com/news/encore-dermatology-inc-a-new-specialty-dermatology-company/2458942/Encore Dermatology, Inc. announced has begun to commercialize Hylatopic®, Tetrix™, and BenzEFoam™, three established topical dermatology products acquired from Valeant Pharmaceuticals North America, LLC and certain of its affiliates. Encore Dermatology, Inc. is a privately
- ASDS Releases Consensus Recommendations on Basal Cell Carcinomahttps://practicaldermatology.com/news/asds-releases-consensus-recommendations-on-basal-cell-carcinoma/2458947/An expert group of dermatologic surgeons appointed by the American Society for Dermatologic Surgery (ASDS) Board of Directors has developed the first-ever consensus recommendations on the treatment and management of basal cell carcinoma (BCC). According to the ASDS, the document is intend
- New Research Finds TriCalm Hydrogel's Itch Relief Superior to Leading OTC Treatmentshttps://practicaldermatology.com/news/new-research-finds-tricalm-hydrogels-itch-relief-superior-to-leading-otc-treatments/2458949/A study conducted to assess the antipruritic effect of over-the-counter (OTC) steroid-free topical hydrogel formulation TriCalm® in reducing itch intensity and duration, has been published in Clinical, Cosmetic, and Investigational Dermatology. The study, which utilized a co
- Foamix Pharmaceuticals Ltd. Closes Its $69 Million Public Offering of Ordinary Shareshttps://practicaldermatology.com/news/foamix-pharmaceuticals-ltd-closes-its-69-million-public-offering-of-ordinary-shares/2458956/Foamix Pharmaceuticals Ltd. closed its follow-on public offering. A total of 7,419,353 ordinary shares were sold at a price to the public of $9.30 per share. Prior to closing, the underwriters fully exercised their option to purchase 967,741 additional ordinary shares. The net proceeds from the s
- Benzac Acne Solutions Premieres “Insta-Dramedy” Webserieshttps://practicaldermatology.com/news/benzac-acne-solutions-premieres-insta-dramedy-webseries/2458955/Galderma Laboratories, L.P launched its first webisode series, “The Benzacs,” a teen insta-dramedy told through 15-second Instagram videos and more than 80 images and short videos. The webseries features the new over-the-counter (OTC) acne treatment Benzac® Acne Solutions, which c
- Provectus Biopharmaceuticals, Pfizer Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancerhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-pfizer-receive-patent-allowance-for-use-of-pv-10-in-combination-with-systemic-immunotherapy-agents-in-treatment-of-cancer/2458962/Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company, announced today that it has received from the US Patent and Trademark Office a N
- Foamix Pharmaceuticals Announces Upsizing and Pricing of Its Public Offeringhttps://practicaldermatology.com/news/foamix-pharmaceuticals-announces-upsizing-and-pricing-of-its-public-offering/2458968/Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), a specialty pharmaceutical company focused on developing topical foams to address unmet needs in dermatology, today announced the pricing of an upsized public offering of 6,451,612 ordinary shares at a price to the public of $9.30 per share. In addition,
- Cipher Pharmaceuticals Acquires Innocutishttps://practicaldermatology.com/news/cipher-pharmaceuticals-acquires-innocutis/2458969/Cipher Pharmaceuticals Inc. has acquired Innocutis Holdings LLC, a privately held specialty dermatology company, for US$45.5 million in cash. (All financial references are in U.S. dollars unless otherwise noted.) "This acquisition marks our commercial entry to the U.S. market an